Toboroz
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
NCT07452458· 3. fázis· NRG Oncology· Forrás
Contact: Joseph A. Bovi (principal investigator)
Toboroz
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
NCT06524544· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Joyce Philip (principal investigator)
Toboroz
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
NCT06931340· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Joyce Philip (principal investigator)
Toboroz
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
NCT07018869· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Emily Pohl (principal investigator)
Fut, nem toboroz
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
NCT06732401· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Joyce Philip (principal investigator)
Toboroz
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204· Wake Forest University Health Sciences· Forrás
Contact: Molly Schumacher (principal investigator)
Fut, nem toboroz
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources
NCT06383988· Wake Forest University Health Sciences· Forrás
Toboroz
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Yazhini Vallatharasu (principal investigator)
Toboroz
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Yazhini Vallatharasu (principal investigator)
Toboroz
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Yazhini Vallatharasu (principal investigator)
Fut, nem toboroz
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
NCT06538038· PrECOG, LLC.· Forrás
Toboroz
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Yazhini Vallatharasu (principal investigator)
Toboroz
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Matthias Weiss (principal investigator)
Toboroz
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06096844· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Matthias Weiss (principal investigator)
Toboroz
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Yazhini Vallatharasu (principal investigator)
Toboroz
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
NCT06295367· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Alyssa Mader (principal investigator)
Fut, nem toboroz
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
NCT06106308· 2. fázis· Cardiff Oncology· Forrás
Fut, nem toboroz
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
NCT05564403· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Joyce Philip (principal investigator)
Fut, nem toboroz
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT05554367· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
NCT06073431· University of Rochester· Forrás
Contact: Julia Stoffel (principal investigator)
Toboroz
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT05976763· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Yazhini Vallatharasu (principal investigator)
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Shannon Schmidt (principal investigator)
Fut, nem toboroz
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828· ECOG-ACRIN Cancer Research Group· Forrás
Toboroz
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Yazhini Vallatharasu (principal investigator)
Toboroz
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
NCT05890352· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: Yazhini Vallatharasu (principal investigator)
Toboroz
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Shannon Schmidt (principal investigator)
Fut, nem toboroz
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
NCT05710406· 2/3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Shannon Schmidt (principal investigator)
Fut, nem toboroz
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
NCT05694871· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Matthias Weiss (principal investigator)
Fut, nem toboroz
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602· 3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
NCT05438212· 3. fázis· NRG Oncology· Forrás
Toboroz
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069· Alliance for Clinical Trials in Oncology· Forrás
Contact: Matthias Weiss (principal investigator)
Fut, nem toboroz
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
NCT05308446· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· 2/3. fázis· NRG Oncology· Forrás
Contact: Matthias Weiss (principal investigator)
Toboroz
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114· Tempus AI· Forrás
Contact: Rachel Luedtke
Toboroz
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
NCT05234177· Tempus AI· Forrás
Contact: Rachel Luedtke
Toboroz
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
NCT05001880· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Matthias Weiss (principal investigator)
Fut, nem toboroz
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
NCT04751370· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084· 3. fázis· NRG Oncology· Forrás
Toboroz
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
NCT04628767· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Matthias Weiss (principal investigator)
Toboroz
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444· Guardant Health, Inc.· Forrás
Contact: Sarah Loether
Fut, nem toboroz
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
NCT04829539· 3. fázis· University of Rochester NCORP Research Base· Forrás
Toboroz
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT04858334· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Matthias Weiss (principal investigator)
Fut, nem toboroz
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NCT04804644· 3. fázis· NRG Oncology· Forrás
Toboroz
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
NCT04671667· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Matthias Weiss (principal investigator)
Showing 50 of 102.